$IGC
IGC Pharma Inc Stock $igc

$igc Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000118518524000766 Filed on August 07, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$412.0K	$272.0K	$555.0K
YoY Change	41.58%	-50.99%	161.79%
Cost Of Revenue	$214.0K	$109.0K	$300.0K
YoY Change	82.91%	-63.67%	328.57%
Gross Profit	$198.0K	$163.0K	$255.0K
YoY Change	13.79%	-36.08%	79.58%
Gross Profit Margin	48.06%	59.93%	45.95%
Selling, General & Admin	$1.041M	$1.670M	$1.647M
YoY Change	-25.48%	1.4%	6.26%
% of Gross Profit	525.76%	1024.54%	645.88%
Research & Development	$917.0K	$889.0K	$747.0K
YoY Change	-27.68%	19.01%	-46.41%
% of Gross Profit	463.13%	545.4%	292.94%
Depreciation & Amortization	$145.0K	$162.0K	$155.0K
YoY Change	3.57%	4.52%	-4.32%
% of Gross Profit	73.23%	99.39%	60.78%
Operating Expenses	$1.958M	$2.559M	$2.394M
YoY Change	-26.53%	6.89%	-18.68%
Operating Profit	-$1.760M	-$2.396M	-$2.139M
YoY Change	-29.35%	12.01%	-23.66%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	$43.00K	$18.00K	$64.00K
YoY Change	7.5%	-71.88%	276.47%
Pretax Income	-$1.717M	-$2.378M	-$2.075M
YoY Change	-29.95%	14.6%	-25.49%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.717M	-$2.378M	-$2.075M
YoY Change	-29.95%	14.6%	-25.49%
Net Earnings / Revenue	-416.75%	-874.26%	-373.87%
Basic Earnings Per Share	-$0.02
Diluted Earnings Per Share	-$0.02	-$0.03	-$0.04
COMMON SHARES
Basic Shares Outstanding	75.64M shares	75.64M shares	53.08M shares
Diluted Shares Outstanding	76.01M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$1.824M	$1.950M
YoY Change		-6.46%	-75.79%
Cash & Equivalents	$1.546M	$1.824M	$1.723M
Short-Term Investments			$227.0K
Other Short-Term Assets	$198.0K	$240.0K	$193.0K
YoY Change	38.46%	24.35%	-23.11%
Inventory	$1.510M	$1.510M	$2.641M
Prepaid Expenses
Receivables	$44.00K	$28.00K	$225.0K
Other Receivables		$51.00K	$0.00
Total Short-Term Assets	$4.250M	$4.407M	$5.078M
YoY Change	-30.52%	-13.21%	-60.1%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.468M	$3.586M	$8.104M
YoY Change	-56.36%	-55.75%	-11.54%
Goodwill
YoY Change
Intangibles	$1.803M	$1.720M	$1.179M
YoY Change	52.67%	45.89%	25.83%
Long-Term Investments
YoY Change
Other Assets	$687.0K	$688.0K	$1.017M
YoY Change	-31.16%	-32.35%	10.3%
Total Long-Term Assets	$6.119M	$6.187M	$10.60M
YoY Change	-41.1%	-41.6%	-7.38%
TOTAL ASSETS
Total Short-Term Assets	$4.250M	$4.407M	$5.078M
Total Long-Term Assets	$6.119M	$6.187M	$10.60M
Total Assets	$10.37M	$10.59M	$15.67M
YoY Change	-37.18%	-32.41%	-35.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$768.0K	$771.0K	$672.0K
YoY Change	39.89%	14.73%	47.37%
Accrued Expenses	$2.034M	$1.718M	$1.459M
YoY Change	30.64%	17.75%	21.58%
Deferred Revenue
YoY Change
Short-Term Debt	$3.000K	$3.000K	$3.000K
YoY Change	0.0%	0.0%	0.0%
Long-Term Debt Due		$3.000K	$3.000K
YoY Change		0.0%	0.0%
Total Short-Term Liabilities	$2.802M	$2.489M	$2.131M
YoY Change	33.05%	16.8%	28.45%
LONG-TERM LIABILITIES
Long-Term Debt	$135.0K	$136.0K	$140.0K
YoY Change	-2.88%	-2.86%	-2.1%
Other Long-Term Liabilities	$20.00K	$20.00K	$21.00K
YoY Change	17.65%	-4.76%	31.25%
Total Long-Term Liabilities	$190.0K	$225.0K	$340.0K
YoY Change	-37.09%	-33.82%	-27.19%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.802M	$2.489M	$2.131M
Total Long-Term Liabilities	$190.0K	$225.0K	$340.0K
Total Liabilities	$2.992M	$2.714M	$2.471M
YoY Change	24.25%	9.83%	16.23%
SHAREHOLDERS EQUITY
Retained Earnings	-$117.8M	-$116.0M	-$102.7M
YoY Change	11.95%	12.95%	11.74%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$7.377M	$7.880M	$13.20M
YoY Change
Total Liabilities & Shareholders Equity	$10.37M	$10.59M	$15.67M
YoY Change	-37.18%	-32.41%	-35.14%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$1.717M	-$2.378M	-$2.075M
YoY Change	-29.95%	14.6%	-25.49%
Depreciation, Depletion And Amortization	$145.0K	$162.0K	$155.0K
YoY Change	3.57%	4.52%	-4.32%
Cash From Operating Activities		-$1.752M	-$1.468M
YoY Change		19.35%	-33.15%
INVESTING ACTIVITIES
Capital Expenditures		$38.00K	$20.00K
YoY Change		90.0%	-84.25%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$43.00K
YoY Change		-100.0%
Cash From Investing Activities		-$131.0K	-$5.000K
YoY Change		2520.0%	-96.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$2.507M	-$1.000K
YoY Change		-250800.0%	0.0%
NET CHANGE
Cash From Operating Activities		-$1.752M	-$1.468M
Cash From Investing Activities		-$131.0K	-$5.000K
Cash From Financing Activities		$2.507M	-$1.000K
Net Change In Cash		$626.0K	-$1.473M
YoY Change		-142.5%	-38.8%
FREE CASH FLOW
Cash From Operating Activities		-$1.752M	-$1.468M
Capital Expenditures		$38.00K	$20.00K
Free Cash Flow		-$1.790M	-$1.488M
YoY Change		20.3%	-35.94%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Other Receivables OtherReceivables	686000	usd
CY2024Q2	dei	Entity Registrant Name EntityRegistrantName	IGC PHARMA, INC.
CY2024Q2	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	MD
CY2024Q2	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2760393
CY2024Q2	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20854
CY2024Q2	dei	Document Type DocumentType	10-Q
CY2024Q2	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q2	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024Q2	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q2	dei	Entity Address Address Line1 EntityAddressAddressLine1	10224 Falls Road
CY2024Q2	dei	Entity Address City Or Town EntityAddressCityOrTown	Potomac
CY2024Q2	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2024Q2	dei	City Area Code CityAreaCode	301
CY2024Q2	dei	Local Phone Number LocalPhoneNumber	983-0998
CY2024Q2	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2024Q2	dei	Trading Symbol TradingSymbol	IGC
CY2024Q2	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
CY2024Q2	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q2	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q2	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q2	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q2	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q2	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	75636419	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1824000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1198000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	39000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1510000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1540000	usd
CY2024Q2	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	720000	usd
CY2024Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	720000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	325000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	208000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	4407000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	3705000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1720000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1616000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3586000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3695000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	193000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	6187000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	6197000	usd
CY2024Q2	us-gaap	Assets Assets	10594000	usd
CY2024Q1	us-gaap	Assets Assets	9902000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	771000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	773000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1718000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1567000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2489000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	2340000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	136000	usd
CY2024Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	137000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	69000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	84000	usd
CY2024Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	225000	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	241000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	2714000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	2581000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75636419	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	75636419	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	66691195	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	66691195	shares
CY2024Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	127349000	usd
CY2024Q1	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	124409000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3426000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3423000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-116043000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113665000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	7880000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7321000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10594000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	9902000	usd
CY2024Q2	us-gaap	Revenues Revenues	272000	usd
CY2023Q2	us-gaap	Revenues Revenues	555000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	109000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	300000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	163000	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	255000	usd
CY2024Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1670000	usd
CY2023Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1647000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	889000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	747000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2396000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2139000	usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	18000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	64000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2378000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2075000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-2378000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2075000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-3000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	9000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2381000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2066000	usd
CY2024Q2	igc	Earnings Per Share Basic Diluted EarningsPerShareBasicDiluted	-0.03
CY2023Q2	igc	Earnings Per Share Basic Diluted EarningsPerShareBasicDiluted	-0.04
CY2024Q2	igc	Weighted Average Number Of Share Outstanding Basic Diluted WeightedAverageNumberOfShareOutstandingBasicDiluted	72813538	shares
CY2023Q2	igc	Weighted Average Number Of Share Outstanding Basic Diluted WeightedAverageNumberOfShareOutstandingBasicDiluted	53077436	shares
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	14911000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	357000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2075000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	9000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	13202000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	7321000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	433000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2507000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2378000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-3000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	7880000	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	-2378000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2075000	usd
CY2024Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	162000	usd
CY2023Q2	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	155000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	402000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	357000	usd
CY2024Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	0	usd
CY2023Q2	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	53000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-11000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	118000	usd
CY2024Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-30000	usd
CY2023Q2	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-10000	usd
CY2024Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	118000	usd
CY2023Q2	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-33000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
CY2023Q2	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	13000	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2000	usd
CY2023Q2	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	142000	usd
CY2024Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	151000	usd
CY2023Q2	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	91000	usd
CY2024Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-5000	usd
CY2023Q2	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-31000	usd
CY2024Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-15000	usd
CY2023Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-28000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1752000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1468000	usd
CY2024Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	38000	usd
CY2023Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20000	usd
CY2024Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2023Q2	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	43000	usd
CY2024Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	93000	usd
CY2023Q2	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	28000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-131000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5000	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2508000	usd
CY2023Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2024Q2	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-1000	usd
CY2023Q2	us-gaap	Proceeds From Repayments Of Debt ProceedsFromRepaymentsOfDebt	-1000	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2507000	usd
CY2023Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1000	usd
CY2024Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2000	usd
CY2023Q2	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	626000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1473000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1198000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3196000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1824000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1723000	usd
CY2024Q2	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	433000	usd
CY2023Q2	us-gaap	Other Significant Noncash Transaction Value Of Consideration Given1 OtherSignificantNoncashTransactionValueOfConsiderationGiven1	357000	usd
CY2024Q2	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 1 </b>–<b> BUSINESS DESCRIPTION</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Overview</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IGC Pharma, a clinical-stage company developing treatments for Alzheimer’s disease, is committed to transforming patient care by striving to offer faster-acting and more effective solutions. Our leading drug candidate, IGC-AD1, embodies this vision by tackling a critical challenge – managing agitation in Alzheimer’s dementia. Early results from our Phase 2 trial are promising: IGC-AD1 effectively reduced agitation in patients compared to a placebo, and crucially, it did so much faster than traditional medications. While existing anti-psychotics can take a long 6 to 12 weeks to show effects, IGC-AD1 has the potential to act within two weeks. This significantly faster onset of action could significantly improve patient care and represents a potential breakthrough in managing Alzheimer’s-related agitation, although there can be no assurance thereof.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We currently have five platforms, each with a core molecule that can be modified. For example, the TGR family consists of many molecules, such as TGR-60, TGR-61, and TGR-63. TGR-63 targets plaques in Alzheimer’s. Similarly, the IGC-C and IGC-M platforms consist of many molecules. The Alzheimer’s targeting molecule from each of our platforms is set forth below:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 50pt;text-indent:-14pt;">● <b>IGC-AD1:</b> Our lead investigational drug tackles agitation, a major burden for patients and caregivers. By addressing neuroinflammation, it has the potential to offer a faster-acting solution compared to traditional medications.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 50pt;text-indent:-14pt;">● <b>TGR-63:</b> Through pre-clinical studies, TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 50pt;text-indent:-14pt;">● <b>IGC-1C:</b> At the preclinical stage, IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 50pt;text-indent:-14pt;">● <b>IGC-M3:</b> Also in preclinical development, IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 43pt;text-indent:-7pt;">● <b>LMP:</b> In preclinical development, LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles, for a comprehensive therapeutic effect.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are also developing Artificial Intelligence (“AI”) models for predicting early Alzheimer’s detection biomarkers, optimizing clinical trials, and to help us explore new disease applications for our molecules. For example, our AI models are being developed to predict the probability that our molecules can work on other receptors, such as GLP1 (neurological disorders, weight loss), CB1 (neuropsychiatric conditions), among others. Additionally, our 26 patent filings, including for IGC-AD1, demonstrate our commitment to innovation and protecting our intellectual property. Collectively, these core assets and initiatives underscore our commitment to advancing the field of pharmaceuticals, delivering groundbreaking treatments, and creating lasting value for our investors. We remain steadfast in our pursuit of excellence and our mission to improve the lives of those affected by Alzheimer’s and related conditions.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IGC is a Maryland corporation established in 2005 with a fiscal year ending on March 31, spanning a 52- or 53-week period. IGC has two business segments: Life Sciences Segment and Infrastructure Segment. For more information on the business segments, please refer to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Phase 2 Clinical Trial</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">IGC Pharma launched a Phase 2 trial with a protocol titled “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled, trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease” (clinicaltrials.gov, Identifier: CT05543681). The study is powered to include 146 Alzheimer’s patients; as a superiority trial with parallel groups; half of the participants will receive a placebo, and the other half will receive IGC-AD1.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The primary and secondary endpoints are the mean change in agitation scores from baseline, compared to placebo, as assessed by the Cohen-Mansfield Agitation Inventory (“CMAI”) in Alzheimer’s patients after 6 weeks of treatment and the mean change in CMAI scores after 2 weeks of treatment, respectively. Agitation is rated at the trial site, at baseline, week 2, and week 6, by a trained practitioner using the CMAI, a scale designed and widely used to measure agitation in Alzheimer’s dementia (“AAD”) in clinical trials. The IGC-AD1 Phase 2 is an ongoing clinical trial that continues to enroll. IGC-AD1 is an oral liquid formulation administered twice daily (“bid”) for six weeks with no placebo run-in and titration to full dose over two days. To date over 1,000 oral doses have been administered, with no dose-limiting adverse events observed, highlighting the safety profile of IGC-AD1. The investigational product potentially targets different pathways implicated in agitation in Alzheimer’s dementia (“AAD”), including CB1 receptor dysfunction, neuroinflammation, and neurotransmitter imbalance.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>AI / Machine Learning (</b>“<b>ML</b>”<b>)</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In our pursuit of innovation, we leverage AI and ML. AI refers to the development of intelligent systems that can learn and act autonomously. ML is a branch of AI that allows computers to learn from data without the need for explicit programming. This technology plays a vital role in our efforts and could allow companies our size to do what previously was the domain of much larger pharmaceutical companies. For instance, we are utilizing ML by training transformers, a powerful neural network architecture, to analyze vast datasets from our Phase 1 and unblinded Phase 2 interim clinical trial to identify patterns and optimize the clinical trial protocol for a potential Phase 3 trial. The AI model, for example, can tell us if a particular neuropsychiatric scale that we used in Phase 1 and Phase 2 added valuable information to the trial, and if it did not, we could remove that scale from a future Phase 3 trial, thus saving money and time in the overall trial management. In the long term, with more data, the trained AI model could allow us to consider incoming patient signatures and predict outcomes for our drug, including adverse effects, thus personalizing the delivery of IGC-AD1.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Additionally, we are developing AI models that help us explore potential applications of molecules from our platforms beyond their initial Alzheimer’s targets; we know that TGR-63 and IGC-M3 target plaques in Alzheimer’s, however, AI models could help us consider applications of TGR-60, TGR-61, IGC-M1, IGC-M2, and many others. For example, we are investigating whether our molecules might interact with other receptors, like GLP-1. GLP-1 is a receptor linked to regulating blood sugar and is increasingly being studied for its potential role in neurological disorders, in addition to its established role in weight management. A successful link between our molecules and other targets potentially expands our opportunities, as some of these other markets, such as the weight loss market, are considerably larger than the Alzheimer’s market. These applications could potentially lead, if proven in future clinical trials, to new treatment avenues and broader market reach for our molecules. This analysis also potentially allows us to prioritize work on our molecules and optimize our resources.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Business Organization</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of June 30, 2024, the Company had the following operating subsidiaries: IGCare LLC, HH Processors, LLC, IGC Pharma, LLC, IGC Pharma IP, LLC, SAN Holdings, LLC, Sunday Seltzer, LLC, Hamsa Biopharma India Pvt. Ltd., Techni Bharathi Private Limited (TBL), and Colombia-based beneficially-owned subsidiary IGC Pharma SAS. The Company’s fiscal year is the 52- or 53-week period that ends on March 31. The Company’s principal office is in Maryland, established in 2005. Additionally, the Company has offices in Washington state, Colombia, South America, and India. The Company’s filings are available on <span style="-sec-extract:exhibit;"><span style="text-decoration:underline">www.sec.gov</span></span>.</p>
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	199000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	181000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	672000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	689000	usd
CY2024Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	1048000	usd
CY2024Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	927000	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1720000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1616000	usd
CY2024Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	20000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	18000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	88000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	97000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	106000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	117000	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	129000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6168000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6137000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2582000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2442000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3586000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3695000	usd
CY2024Q2	us-gaap	Depreciation Depreciation	142000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	137000	usd
CY2024Q1	us-gaap	Land Available For Sale LandAvailableForSale	720000	usd
CY2023Q1	us-gaap	Land Land	4100000	usd
CY2024Q2	us-gaap	Proceeds From Deposits On Real Estate Sales ProceedsFromDepositsOnRealEstateSales	180000	usd
CY2024Q3	us-gaap	Land Available For Sale LandAvailableForSale	717000	usd
CY2024Q2	igc	Going Concern Policy Policy Textblock GoingConcernPolicyPolicyTextblock	<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Going Concern</b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, “<i>Presentation of Financial Statements</i>—<i>Going Concern</i>”, which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur significant operating and net losses and negative cash flows from operations in the near future.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company estimates that its current cash and cash equivalents balance with the working capital and equity investment is sufficient to support operations beyond the twelve months following the date these consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects.</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2024Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	28000	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24000	usd
CY2024Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	39000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	24000	usd
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11000000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	72813538	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	53077436	shares
CY2024Q2	us-gaap	Revenues Revenues	272000	usd
CY2023Q2	us-gaap	Revenues Revenues	555000	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1077000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	1099000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	36000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	0	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	397000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	441000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1510000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1540000	usd
CY2024Q2	us-gaap	Inventory Write Down InventoryWriteDown	26000	usd
CY2023Q2	us-gaap	Inventory Write Down InventoryWriteDown	20000	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	34000	usd
CY2024Q1	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	41000	usd
CY2024Q2	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	51000	usd
CY2024Q1	us-gaap	Other Inventory Net Of Reserves OtherInventoryNetOfReserves	52000	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	240000	usd
CY2024Q1	us-gaap	Other Assets Current OtherAssetsCurrent	115000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	325000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	208000	usd
CY2024Q2	igc	Statutory Advances StatutoryAdvances	34000	usd
CY2024Q1	igc	Statutory Advances StatutoryAdvances	39000	usd
CY2024Q2	us-gaap	Other Receivables OtherReceivables	686000	usd
CY2024Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2000	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	2000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1012000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	816000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	156000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	208000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	133000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	124000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	417000	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	419000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1718000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1567000	usd
CY2024Q2	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	23000	usd
CY2024Q1	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	25000	usd
CY2024Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	3000	usd
CY2024Q1	us-gaap	Short Term Borrowings ShortTermBorrowings	3000	usd
CY2020Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000	usd
CY2020Q2	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0375	pure
CY2020Q2	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	731000	usd
CY2020Q2	us-gaap	Debt Instrument Term DebtInstrumentTerm	P30Y
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1000	usd
CY2024Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	1000	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	1000	usd
CY2023Q2	us-gaap	Repayments Of Debt RepaymentsOfDebt	1000	usd
CY2024Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	136000	usd
CY2024Q2	us-gaap	Loans Payable Current LoansPayableCurrent	3000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	20000	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	20000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	20000	usd
CY2024Q2	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.06	pure
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	75636419	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	igc	Units Outstanding UnitsOutstanding	91472	shares
CY2024Q2	igc	Unit Description UnitDescription	Ten units may be separated into one share of common stock.
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	4600000	usd
CY2024Q2	igc	Weighted Average Price Per Share WeightedAveragePricePerShare	0.61
CY2024Q2	us-gaap	Stock Issued During Period Shares Restricted Stock Award Gross StockIssuedDuringPeriodSharesRestrictedStockAwardGross	4900000	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1	pure
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	1	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0415	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0524	pure
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.75	pure
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.75	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7452000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.62
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	0	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	100000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.43
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	0	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7352000	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.61
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3710000	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.25
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2024Q2	igc	Exercised Weighted Average Grant Date Fair Value ExercisedWeightedAverageGrantDateFairValue	0
CY2024Q2	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	0	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3710000	shares
CY2024Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.25
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.29
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P4Y
CY2024Q2	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	1824000	usd
CY2024Q2	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	0	usd
CY2024Q2	us-gaap	Fair Value Assets And Liabilities Measured On Recurring Basis Gain Loss Included In Earnings FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings	0	usd
CY2024Q2	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1824000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1824000	usd
CY2024Q2	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	0	usd
CY2024	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	1198000	usd
CY2024	us-gaap	Fair Value Asset Liability Recurring Basis Still Held Unrealized Gain Loss FairValueAssetLiabilityRecurringBasisStillHeldUnrealizedGainLoss	0	usd
CY2024	us-gaap	Fair Value Assets And Liabilities Measured On Recurring Basis Gain Loss Included In Earnings FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings	0	usd
CY2024Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	1198000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1198000	usd
CY2024Q1	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	0	usd
CY2024Q2	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	pure
CY2024Q2	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	pure
CY2024Q2	us-gaap	Revenues Revenues	272000	usd
CY2023Q2	us-gaap	Revenues Revenues	555000	usd
CY2024Q2	us-gaap	Revenues Revenues	272000	usd
CY2024Q2	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2023Q2	us-gaap	Revenues Revenues	555000	usd
CY2023Q2	igc	Total Revenue Percentage TotalRevenuePercentage	1	pure
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1720000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3586000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	193000	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	6187000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1616000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3695000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	688000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	198000	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	6197000	usd
CY2024Q3	us-gaap	Land Available For Sale LandAvailableForSale	717000	usd
CY2024Q3	us-gaap	Line Of Credit Facility Current Borrowing Capacity LineOfCreditFacilityCurrentBorrowingCapacity	12000000	usd
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	dei	Amendment Flag AmendmentFlag	false
CY2024Q2	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2024Q2	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q2	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2025
CY2024Q2	dei	Entity Central Index Key EntityCentralIndexKey	0001326205

Files In Submission

Name	View Source	Status
0001185185-24-000766-index-headers.html	Edgar Link	pending
0001185185-24-000766-index.html	Edgar Link	pending
0001185185-24-000766.txt	Edgar Link	pending
0001185185-24-000766-xbrl.zip	Edgar Link	pending
ex_709380.htm	Edgar Link	pending
ex_709381.htm	Edgar Link	pending
ex_709382.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
igc-20240630.xsd	Edgar Link	pending
igc20240630_10q.htm	Edgar Link	pending
igcpharma_001.jpg	Edgar Link	pending
igcpharma_002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
igc-20240630_cal.xml	Edgar Link	unprocessable
igc-20240630_lab.xml	Edgar Link	unprocessable
igc-20240630_def.xml	Edgar Link	unprocessable
igc-20240630_pre.xml	Edgar Link	unprocessable
igc20240630_10q_htm.xml	Edgar Link	completed
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$IGC
IGC Pharma Inc Stock $igc

2024 Q3 Form 10-Q Financial Statement

#000118518524000766 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IGC IGC Pharma Inc Stock $igc

2024 Q3 Form 10-Q Financial Statement

#000118518524000766 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$IGC
IGC Pharma Inc Stock $igc